Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

52
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
52
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

141
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
141
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

140
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
140
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

75
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
75
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

40
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
40
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

122
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
122

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interdisciplinary Clinical Practice Guidelines for patient-centred management of juvenile-onset systemic lupus erythematosus.

EULAR rheumatology open·2026
Same author

Evidence- and Consensus-based European Guideline for Immunosuppressive Therapy After Pediatric Kidney Transplantation.

Transplantation·2026
Same author

Mycophenolate dosing in childhood nephrotic syndrome - Authors' reply.

The Lancet. Child & adolescent health·2026
Same author

Risk Assessment of Delayed Graft Function in Pediatric Kidney Transplantation - a CERTAIN Research Network Analysis.

Transplant international : official journal of the European Society for Organ Transplantation·2026
Same author

Lipid Metabolism and Obesity in Early Life: Drivers of Chronic Lung Disease From Development to Adulthood.

Molecular nutrition & food research·2026
Same author

Antibiotic prophylaxis in the context of VCUG/VUS in children: results of a multinational survey.

BMC pediatrics·2026
Same journal

For health, for beauty, or both? navigating trends as adolescent clinicians.

Current opinion in pediatrics·2026
Same journal

Childhood sleep disorders: practical management for the pediatrician.

Current opinion in pediatrics·2026
Same journal

Advanced therapies in management of pediatric inflammatory bowel disease.

Current opinion in pediatrics·2026
Same journal

Artificial intelligence in pediatric endoscopy for hereditary polyposis syndromes: promises and challenges.

Current opinion in pediatrics·2026
Same journal

Hormonal acne therapies in pediatrics.

Current opinion in pediatrics·2026
Same journal

Clinical implementation of artificial intelligence in adolescent mental healthcare.

Current opinion in pediatrics·2026
See all related articles

Related Experiment Video

Updated: Oct 4, 2025

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

7.8K

IgA vasculitis nephritis.

Eva Nüsken1, Lutz T Weber

  • 1Pediatric Nephrology, Children's and Adolescents' Hospital, University Hospital of Cologne, Faculty of Medicine, University of Cologne, Köln, Germany.

Current Opinion in Pediatrics
|February 7, 2022
PubMed
Summary
This summary is machine-generated.

Immunoglobulin A (IgA) vasculitis nephritis (IgAVN) involves complex pathophysiology with potential therapeutic targets. Early diagnosis and treatment are crucial, but more research is needed for evidence-based recommendations.

More Related Videos

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.3K
Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
09:16

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis

Published on: June 18, 2020

7.0K

Related Experiment Videos

Last Updated: Oct 4, 2025

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

7.8K
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.3K
Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis
09:16

Supervised Machine Learning for Semi-Quantification of Extracellular DNA in Glomerulonephritis

Published on: June 18, 2020

7.0K

Area of Science:

  • Nephrology
  • Immunology
  • Pathophysiology

Background:

  • Immunoglobulin A (IgA) vasculitis nephritis (IgAVN) is a complex condition with a multilevel pathogenesis.
  • Key pathways include Toll-like receptor activation, B cell proliferation, micro-RNAs, and complement activation.

Purpose of the Study:

  • To summarize current knowledge on IgAVN pathophysiology.
  • To review evidence for existing therapies and biomarkers.
  • To identify areas for future research to improve understanding, risk stratification, and treatment.

Main Methods:

  • Review of clinical and experimental studies.
  • Analysis of established and emerging therapeutic targets.
  • Evaluation of current diagnostic biomarkers.

Main Results:

  • Multilevel pathogenesis identified with several potential therapeutic targets.
  • Promising urinary biomarkers for early diagnosis include kidney injury molecule-1, monocyte chemotactic protein-1, N-acetyl-β-glucosaminidase, and angiotensinogen.
  • Current therapeutic evidence is largely based on expert opinion.

Conclusions:

  • Close surveillance for renal involvement in IgA vasculitis patients is recommended.
  • Early treatment, even for mild cases, is advised due to the complex pathogenesis.
  • Further prospective studies are needed, focusing on therapies targeting B cell proliferation and complement activation.